Cited by

• Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain.

  Smaoui MR, Yahyaoui H. Smaoui MR, et al. Sci Rep. 2021 Apr 28;11(1):9166. doi: 10.1038/s41598-021-88696-5. Sci Rep. 2021. PMID: 33911163 Free PMC article.
• Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.

  Vitali L, Merlini A, Galvagno F, Proment A, Sangiolo D. Vitali L, et al. Biomedicines. 2022 Oct 19;10(10):2628. doi: 10.3390/biomedicines10102628. Biomedicines. 2022. PMID: 36289890 Free PMC article. Review.
• The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.

  Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Mirian M, Esmaeili Y, Najaflu M, Khanahmad N, Zeinalian M, Trovato M, Tay FR, Khanahmad H, Makvandi P. Kouhpayeh S, et al. Int J Mol Sci. 2021 May 21;22(11):5438. doi: 10.3390/ijms22115438. Int J Mol Sci. 2021. PMID: 34064039 Free PMC article. Review.
• Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease.

  Medjeral-Thomas NR, Troldborg A, Hansen AG, Gisby J, Clarke CL, Prendecki M, McAdoo SP, Sandhu E, Lightstone L, Thomas DC, Willicombe M, Botto M, Peters JE, Pickering MC, Thiel S. Medjeral-Thomas NR, et al. Front Immunol. 2021 Apr 29;12:671052. doi: 10.3389/fimmu.2021.671052. eCollection 2021. Front Immunol. 2021. PMID: 33995410 Free PMC article. Clinical Trial.
• Antibody-mediated SARS-CoV-2 entry in cultured cells.

  Kibria MG, Lavine CL, Tang W, Wang S, Gao H, Shi W, Zhu H, Voyer J, Rits-Volloch S, Keerti, Bi C, Peng H, Wesemann DR, Lu J, Xie H, Seaman MS, Chen B. Kibria MG, et al. EMBO Rep. 2023 Dec 6;24(12):e57724. doi: 10.15252/embr.202357724. Epub 2023 Nov 2. EMBO Rep. 2023. PMID: 38277394 Free PMC article.